Company logo

RYTM - Rhythm Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
Boston, United States
Type: Equity

RYTM price evolution
RYTM
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $162.13 $53.89 $60.41
Short term investments $157.46 $147.77 $215.76
Net receivables $19.31 $17.6 $14.7 $14.87
Inventory $13.89 $11.99 $8.51 $8.62
Total current assets $340.34 $357.37 $235.75 $308.27
Long term investments
Property, plant & equipment $4.39 $4.67 $1.82 $2.12
Goodwill & intangible assets $6.6 $6.82 $7.03
Total noncurrent assets $24.48 $22.9 $24.48
Total investments $157.46 $147.77 $215.76
Total assets $363.57 $381.85 $258.65 $332.75
Current liabilities
Accounts payable $4.89 $4.54 $7.55 $4.88
Deferred revenue $1.29 $1.29 $1.29
Short long term debt $0.82 $0.79 $0.77
Total current liabilities $97.61 $54.72 $54.16 $55.2
Long term debt $109.24 $3.3 $0.28 $0.49
Total noncurrent liabilities $147.63 $142.91 $107.78
Total debt $4.12 $1.08 $1.26
Total liabilities $210.88 $202.35 $197.07 $162.99
Shareholders' equity
Retained earnings -$1112.01 -$1068.37 -$1036.11 -$894.74
Other shareholder equity -$0.6 -$0.62 -$0.18 $0.13
Total shareholder equity $39.34 $61.58 $169.76
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $60.41 $128 $59.58 $101.26
Short term investments $215.76 $205.61 $235.61 $71.94
Net receivables $14.87 $6.22 $1.02
Inventory $8.62 $2.92
Total current assets $308.27 $354.24 $308.39 $181.67
Long term investments
Property, plant & equipment $2.12 $3.38 $4.33 $5
Goodwill & intangible assets $7.03 $7.88 $4.66
Total noncurrent assets $24.48 $28.25 $21.14 $5.41
Total investments $215.76 $205.61 $235.61 $71.94
Total assets $332.75 $382.48 $329.52 $187.07
Current liabilities
Accounts payable $4.88 $4.8 $5.74 $4.9
Deferred revenue $1.29 $1.43
Short long term debt $0.77 $0.68 $0.61 $0.54
Total current liabilities $55.2 $39.81 $43.43 $17.99
Long term debt $0.49 $75.81 $1.95 $2.55
Total noncurrent liabilities $107.78 $78.41 $1.95 $2.55
Total debt $1.26 $1.94 $2.55 $3.09
Total liabilities $162.99 $118.22 $45.37 $20.55
Shareholders' equity
Retained earnings -$894.74 -$710.06 -$528.94 -$459.33
Other shareholder equity $0.13 -$0.09 -$0 $0.05
Total shareholder equity $169.76 $264.26 $284.15 $166.53
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $33.25 $29.08 $25.97 $24.23
Cost of revenue $2.95 $2.81 $3.23
Gross Profit $29.42 $26.13 $23.16 $21
Operating activities
Research & development $30.19 $128.66 $29.89
Selling, general & administrative $36.41 $34.38 $32.37
Total operating expenses $73.31 $66.61 $163.05 $62.27
Operating income -$40.48 -$139.89 -$41.27
Income from continuing operations
EBIT -$27.18 -$136.32 -$36.89
Income tax expense -$0.34 $0.48 $0.3 $0.2
Interest expense -$1.19 $4.6 $4.75 $4.55
Net income
Net income -$44.97 -$32.26 -$141.37 -$41.63
Income (for common shares) -$33.56 -$141.37 -$41.63
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $77.43 $23.64 $3.15
Cost of revenue $9.3 $2.13 $0.6
Gross Profit $68.13 $21.5 $2.56
Operating activities
Research & development $134.95 $108.63 $104.13 $90.45
Selling, general & administrative $117.53 $92.03 $68.49 $46.13
Total operating expenses $252.48 $200.66 $172.61 $136.57
Operating income -$184.36 -$179.16 -$170.06 -$136.57
Income from continuing operations
EBIT -$170.22 -$175.92 -$69.61 -$134
Income tax expense $0.56
Interest expense $13.89 $5.2
Net income
Net income -$184.68 -$181.12 -$69.61 -$134
Income (for common shares) -$184.68 -$181.12 -$69.61 -$134
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$32.26 -$141.37 -$41.63
Operating activities
Depreciation $0.39 $0.41 $0.42
Business acquisitions & disposals -$40
Stock-based compensation $10.36 $7.77 $8.67
Total cash flows from operations -$29.08 -$40.74 -$29.38
Investing activities
Capital expenditures $0
Investments -$8.56 $70.05 $22.64
Total cash flows from investing -$69.33 -$8.56 $30.05 $22.64
Financing activities
Dividends paid
Sale and purchase of stock $1.4 $7.03 $5
Net borrowings
Total cash flows from financing $152.91 $146.18 $4.24 $2.42
Effect of exchange rate -$0.97 -$0.3 -$0.07 -$0.19
Change in cash and equivalents -$12.43 $108.24 -$6.52 -$4.51
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$184.68 -$181.12 -$69.61 -$134
Operating activities
Depreciation $1.76 $1.67 $1.16 $0.69
Business acquisitions & disposals -$5.67
Stock-based compensation $32.55 $19.83 $20.8 $17.45
Total cash flows from operations -$136.16 -$173.43 -$146 -$121.98
Investing activities
Capital expenditures -$0.05 -$0.28 $99.57 -$0.21
Investments $0.05 $32.31 -$163.72 $158.75
Total cash flows from investing -$5.67 $28.03 -$62.16 $158.53
Financing activities
Dividends paid
Sale and purchase of stock $57.4 $141.49 $166.48 $2.01
Net borrowings $24.37 $72.34
Total cash flows from financing $74.37 $213.83 $166.48 $2.01
Effect of exchange rate -$0.14
Change in cash and equivalents -$67.6 $68.43 -$41.68 $38.56
Fundamentals
Market cap $3.45B
Enterprise value N/A
Shares outstanding 61.44M
Revenue $112.53M
EBITDA N/A
EBIT N/A
Net Income -$260.24M
Revenue Q/Q 47.76%
Revenue Y/Y 81.55%
P/E ratio -13.25
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 30.64
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$4.24
ROA -77.87%
ROE N/A
Debt/Equity 0.96
Net debt/EBITDA N/A
Current ratio 3.49
Quick ratio 3.34